Treatment of Pediatric, Adolescent, and Young Adult Patients With Fusion‐Positive Alveolar Rhabdomyosarcoma Infiltrating Regional Lymph Nodes in the European CWS‐2002P and RMS 2005 Studies and the Soft Tissue Sarcoma Registry
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31476 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Amadeus T Heinz und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology and Oncology, University Children´s Hospital Tuebingen, Tuebingen, Germany. Hauptthemen laut MEDLINE: Rhabdomyosarcoma, Alveolar, Registries, Antineoplastic Combined Chemotherapy Protocols, Lymph Nodes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fondazione Città della Speranza, Alice's Arc, Deutsche Kinderkrebsstiftung.
Abstract (Originalsprache)
Background
Patients with alveolar rhabdomyosarcoma (ARMS) with regional lymph node involvement (N1) are defined as “very‐high‐risk rhabdomyosarcoma” in Europe. Different chemotherapy regimens were used in European study protocols.
Methods
Patients with FOXO1 fusion‐positive N1 ARMS registered in the CWS‐2002P study, the EpSSG RMS 2005 study, and SoTiSaR were retrospectively investigated. Patients received systemic treatment with chemotherapy (CHT) and local treatment of primary tumor (PT) and involved lymph nodes (LN) with radiotherapy (RT) and/or surgery. Kaplan–Meier estimators and Cox regression were used to examine event‐free survival (EFS) and overall survival (OS) according to prognostic factors and treatment.
Results
A total of 156 patients registered in RMS 2005 ( n = 99), CWS‐2002P ( n = 20), and SoTiSaR ( n = 37) between 2003 and 2020 were eligible for this analysis. Median age at diagnosis was 10.2 years [0.1–21.9]. Treatment comprised CHT with IVADo (ifosfamide, vincristine, actinomycin‐D, doxorubicin, n = 93; 60%), VAIA (vincristine, actinomycin‐D, ifosfamide, adriamycin/doxorubicin, n = 53; 34%) or other regimens ( n = 10; 6%); resection of the PT ( n = 89; 57%), LN sampling or dissection ( n = 92; 59%), and/or RT ( n = 139; 89%). Maintenance treatment (MT) was added in n = 99/135 (73%) patients who achieved complete remission. Five‐year EFS and OS of the cohort were 45% and 47%, respectively. Age and tumor size were independent prognostic factors for EFS. Local treatment applied to the LN with surgery, RT or both significantly improved EFS ( p = 0.02) and OS ( p = 0.04), with no difference between the modalities ( p = 0.7).
Conclusions
Patients with fusion‐positive N1 ARMS carry a poor prognosis. Adequate local treatment of LN improved survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Hematology and Oncology, University Children´s Hospital Tuebingen, Tuebingen, Germany.
- Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin (Olgahospital), Pädiatrie 5 (Pädiatrische Onkologie, Hämatologie, Immunologie), Klinikum der Landeshauptstadt Stuttgart, Stuttgart, Germany.
- Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin (Olgahospital), Pädiatrie 2 (Pädiatrische Gastroenterologie), Klinikum der Landeshauptstadt Stuttgart, Stuttgart, Germany.
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
- Division of Imaging and Oncology, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands.
- Network Aging Research, Heidelberg University, Heidelberg, Germany.
ORCID-Profile: Amadeus T Heinz, Véronique Minard-Colin, Christian Vokuhl, Ewa Koscielniak, Julia C Chisholm, Monika Sparber-Sauer, Gianni Bisogno
Förderung
- Fondazione Città della Speranza
- Alice's Arc
- Deutsche Kinderkrebsstiftung
- Foerderkreis Krebskranke Kinder Stuttgart
- German Cancer Aid Foundation
- Royal Marsden Cancer Charity
- National Institute for Health Research
- Royal Marsden NHS Foundation Trust
Zitieren
APA
Heinz, A. T., Ciuffolotti, M., Merks, J. H. M., Schönstein, A., Minard-Colin, V., Fuchs, J., Guillen, G., Timmermann, B., Vokuhl, C., Koscielniak, E., Chisholm, J. C., Sparber-Sauer, M., & Bisogno, G. (2025). Treatment of Pediatric, Adolescent, and Young Adult Patients With Fusion‐Positive Alveolar Rhabdomyosarcoma Infiltrating Regional Lymph Nodes in the European CWS‐2002P and RMS 2005 Studies and the Soft Tissue Sarcoma Registry. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31476
Vancouver
Heinz AT, Ciuffolotti M, Merks JHM, Schönstein A, Minard-Colin V, Fuchs J, et al. Treatment of Pediatric, Adolescent, and Young Adult Patients With Fusion‐Positive Alveolar Rhabdomyosarcoma Infiltrating Regional Lymph Nodes in the European CWS‐2002P and RMS 2005 Studies and the Soft Tissue Sarcoma Registry. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31476
BibTeX
@article{Heinz2025,
author = {Heinz, Amadeus T and Ciuffolotti, Melissa and Merks, Johannes H M and Schönstein, Anton and Minard-Colin, Véronique and Fuchs, Jörg and Guillen, Gabriela and Timmermann, Beate and Vokuhl, Christian and Koscielniak, Ewa and Chisholm, Julia C and Sparber-Sauer, Monika and Bisogno, Gianni},
title = {Treatment of Pediatric, Adolescent, and Young Adult Patients With Fusion‐Positive Alveolar Rhabdomyosarcoma Infiltrating Regional Lymph Nodes in the European CWS‐2002P and RMS 2005 Studies and the Soft Tissue Sarcoma Registry},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31476}
}
EUVIMED